Market Cap | 15.47M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -16.37M | Forward P/E | -0.83 | EPS next Y | - | 50D Avg Chg | 24.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -4.00% |
Dividend | N/A | Price/Book | 0.40 | EPS next 5Y | - | 52W High Chg | -62.00% |
Recommedations | 2.00 | Quick Ratio | 5.71 | Shares Outstanding | 1.04M | 52W Low Chg | 91.00% |
Insider Own | 23.14% | ROA | -37.90% | Shares Float | 761.71K | Beta | 0.74 |
Inst Own | 2.87% | ROE | -63.25% | Shares Shorted/Prior | 419/7.85K | Price | 0.59 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 233,632 | Target Price | - |
Oper. Margin | - | Earnings Date | Aug 13 | Volume | 39,437 | Change | 0.39% |
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
STEINMAN LAWRENCE | Director Director | Jun 02 | Buy | 0.431 | 30,000 | 12,930 | 1,327,174 | 06/06/23 |
Shahinian Eric | Other Other | Sep 28 | Buy | 1.17 | 64,357 | 75,298 | 1,788,415 | 09/30/22 |
Shahinian Eric | Other Other | Sep 01 | Buy | 1.13 | 88,901 | 100,458 | 1,724,058 | 09/06/22 |
Shahinian Eric | Other Other | Aug 29 | Buy | 1.16 | 22,828 | 26,480 | 1,635,157 | 08/31/22 |
Shahinian Eric | - - | Aug 17 | Buy | 1.2087 | 155,773 | 188,283 | 1,611,329 | 08/18/22 |